SCHEMBL10003388

SCHEMBL10003388

CCOC(=O)c1c(OC(C)C)c2nc(-c3ccc(F)cc3)c(CC)nc2n1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA2 P47869 3/20 0.45
▸ GABRB2 P47870 3/20 0.45
▸ ALDH1A1 P00352 5/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ HPGD P15428 4/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ALOX5 P09917 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TRPM8 Q7Z2W7 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ SLC34A1 Q06495 3/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ FAAH O00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003794 0.90 GABRA2 (0.45) GABRA2GABRB2ALDH1A1LMNARAB9A
SCHEMBL10004654 0.89 GRIA2 (0.37) GABRA2GABRB2FAAH
SCHEMBL10003266 0.85 GABRA2 (0.49) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10003449 0.85 GABRA2 (0.44) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10003447 0.83 KDM4E (0.43) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10003197 0.83 GABRA2 (0.45) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10003360 0.80 CYP1A2 (0.47) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10003428 0.79 POLB (0.35) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10004195 0.79 KMT2A (0.36) GABRA2GABRB2ALDH1A1KDM4EHPGD
SCHEMBL10003648 0.79 GABRA2 (0.39) GABRA2GABRB2ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH GABRA2 2197/4885GABRB2 1779/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback